ClinicalTrials.gg
Not yet recruitingNCT07313852Updated Nov 9, 2026

A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia

A Phase 1/2 interventional study of Blinatumomab Injection in B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult and B-ALL, sponsored by Memorial Sloan Kettering Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 9, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies testing blinatumomab in Burkitt Lymphoma — 16 open to participants now, 23 under way, 8 of them phase 3. blinatumomab · Burkitt Lymphoma.

Planned enrollment
25th of 35
26 · median 52
Started
2026
with 3 others
Phase 1/2
5 of 35
2 open now
Primary completion
2029-01
later than 16 of 22 live
Registered
33rd of 35
by date

Among the 35 studies testing blinatumomab in Burkitt Lymphoma, this one is the 25th largest by planned enrollment, is one of 4 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 16 of the 22 other live ones, and was the 33rd registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

16 of the 35 studies testing blinatumomab in Burkitt Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing blinatumomab in Burkitt Lymphoma, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).

03

Conditions studied

  • B-cell Acute Lymphoblastic Leukemia
  • B-Cell Acute Lymphoblastic Leukemia, Adult
  • B-ALL

Browse trials for

Keywords

  • B-cell Acute Lymphoblastic Leukemia
  • B-Cell Acute Lymphoblastic Leukemia, Adult
  • B-ALL
  • Memorial Sloan Kettering Cancer Center
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years of age.
  • Newly diagnosed CD19+ and CD22+ B-ALL with the following characteristics

    • Patients ≥55 years old, OR
    • Patients 18-54 years old who decline or are deemed unfit for conventional chemotherapy with at least one of the following criteria:
  • performance status of 2 or more
  • Severe cardiac comorbidity (including congestive heart failure requiring treatment)
  • Known pulmonary comorbidity (including DLCO ≤65% or ≤65%)
  • Renal comorbidity (including 30-45 mL/min)
  • CD19+ and CD22+ B-ALL
  • Patients with extramedullary disease will be allowed as long as they have detectable disease by flow cytometry in the bone marrow
  • Peripheral absolute lymphoblast count of ≤ 10,000/ml after pre-phase (not required for enrollment but required to proceed with first dose of inotuzumab).
  • Philadelphia chromosome negative by FISH/karyotype for t(19;22) or RT PCR for bcr-abl transcript.
  • CD19 and CD22 expression will be confirmed by enrolling institutions prior to study registration by flow cytometry and/or IHC.
  • Creatinine clearance ≥30 mL/min
  • Total ≤ 1.5 x , and ALT ≤3.0x upper limit of normal (ULN)
  • ≤ 480
  • ≥ 50%

Exclusion criteria

Exclusion Criteria:

  • Patients with Burkitt's lymphoma, T-ALL, CML in lymphoid blast crisis and mixed phenotype acute leukemia (MPAL).
  • Patients with newly diagnosed B-ALL who received prior treatments, with the exception of , hydroxyurea, or one dose of vincristine, are ineligible.
  • Patients with Ph+ B-ALL by FISH or RT PCR.
  • performance status >3.
  • (LVEF) \<50%.
  • History of sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD).
  • Prior treatment with inotuzumab
  • History of liver cirrhosis
  • Ongoing need for systemic T-cell suppressive therapy (e.g. corticosteroids, tacrolimus, cyclosporine, etc.) Patients need to be off calcineurin inhibitors for at least 4 weeks in order to be eligible for enrollment.
  • Active Grade 2-4 acute (GVHD), graded with the modified Glucksberg criteria and/or GVHD requiring systemic steroids in excess of physiologic replacement
  • Moderate or severe chronic GVHD graded with the NIH 2014 criteria
  • Pregnant or lactating women. Women and men of childbearing age should use effective while on this study and continue for the following time periods: female patients of should use effective contraception during treatment and for 8 months after last treatment dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 5 months after the last dose.
  • Patients with or active or infection are ineligible. Patients with a prior history of hepatitis B or hepatitis C who have negative HBV/HCV PCR respectively at the time of screening are eligible
  • Patients with concurrent active as defined by malignancies requiring any therapy other than expectant observation or hormonal therapy, with the exception of squamous and basal cell carcinoma of the skin, in situ cervical cancer, adequately treated stage I/II cancer from which the patient is current in complete remission, or any other cancer from which the patient has been disease free for five years
  • Patients with history or presence of neurological disorders such as epilepsy, generalized seizure disorder, or severe brain injuries.
  • Any other issue which, in the opinion of the treating physician, would make the patient ineligible for the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Phase I: Participants With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

    Participants will be newly diagnosed with CD19+ and CD22+ B-cell Acute Lymphoblastic Leukemia

    Drug: Blinatumomab Injection

  • Experimental
    Phase II: Participants With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

    Participants who receive at least one dose of the Inotuzumab will be evaluable for the primary endpoint

    Drug: Blinatumomab Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Phase I: Maximum Tolerated Dose/MTD

    To establish the MTD in phase 1 part of the study

    Time frame: up to 1 year

  2. Phase II: Rate of MRD negative CR/CRi (10-4 threshold) at the end of induction.

    To evaluate the efficacy of concurrent inotuzumab at the RP2D and subcutaneous blinatumomab in participants as assessed by rate of MRD negative CR/CRi (10-4 threshold) at the end of induction.

    Time frame: up to 1 year

07

Study locations

1 site
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    • Jae Park, MD · Contact646-608-3743
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2029, 25 months later.

Of 50 phase 1/2 interventional studies under Burkitt Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 114. This study's planned 25 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 2, 2026
StartEst.
Dec 2026was Sep 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Dec 2026
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date Sep 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07313852
Collaborators
Amgen, Pfizer
Responsible party
Sponsor
First posted
Jan 2, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Jae Park, MD
Contact
parkj6@mskcc.org
646-608-3743
Mark Geyer, MD
Contact
geyerm@mskcc.org
646-608-3745
Jae Park, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion